Abstract:The use of organoid models in biomedical research has grown substantially since their inception. As they gain popularity among scientists seeking more complex and biologically relevant systems, there is a direct need to expand and clarify potential uses of such systems in diverse experimental contexts. Herein we outline a high-content screening (HCS) platform that allows researchers to screen drugs or other compounds against three-dimensional (3D) cell culture systems in a multi-well format (384-well). Furthermore, we compare the quality of robotic liquid handling with manual pipetting and characterize and contrast the phenotypic effects detected by confocal imaging and biochemical assays in response to drug treatment. We show that robotic liquid handling is more consistent and amendable to high throughput experimental designs when compared to manual pipetting due to improved precision and automated randomization capabilities. We also show that image-based techniques are more sensitive to detecting phenotypic changes within organoid cultures than traditional biochemical assays that evaluate cell viability, supporting their integration into organoid screening workflows. Finally, we highlight the enhanced capabilities of confocal imaging in this organoid screening platform as they relate to discerning organoid drug responses in single-well co-cultures of organoids derived from primary human biopsies and patient-derived xenograft (PDX) models. Altogether, this platform enables automated, imaging-based HCS of 3D cellular models in a non-destructive manner, opening the path to complementary analysis through integrated downstream methods.

The development of high-content screening (HCS) technology and its importance to drug discovery

The latest advances in high content screening in microfluidic devices

Guidelines for Application of High-Content Screening in Traditional Chinese Medicine: Concept, Equipment, and Troubleshooting

Establishment of drug screening in human embryonic stem cells based on a high-content screening system.

Requirements, features, and performance of high content screening platforms

High content screening for drug discovery from traditional Chinese medicine

Advances in high‐throughput mass spectrometry in drug discovery

HCS-3DX, a next-generation AI-driven automated 3D high-content screening system

Advances in high throughput cell culture technologies for therapeutic screening and biological discovery applications

High-throughput screening in multicellular spheroids for target discovery in the tumor microenvironment

Development of an automated 3D high content cell screening platform for organoid phenotyping

Drug Discovery Goes Three-Dimensional: Goodbye to Flat High-Throughput Screening?

Current progress in high-throughput screening for drug repurposing

High-throughput cellular microarray platforms: applications in drug discovery, toxicology and stem cell research

[The role and application of high-throughput screening in the search for chemical compounds of therapeutic activity]

A new approach to assess drug sensitivity in cells for novel drug discovery

Prospects and Challenges of Applying RNAi Combined with High Content Screening in Drug Development

Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening

High-content CRISPR screening

Design and Implementation of High Throughput Screening Assays for Drug Discoveries

A statistical framework for high-content phenotypic profiling using cellular feature distributions